Who
Donal O'Connor
Director
Company insider
Files Form 4 as: Director, Theravance Biopharma; Director, Perrigo Company.
In numbers
- Trades disclosed
- 106
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $82K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 13 Nov 2014
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —74,204 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —24,258 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,398 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —6,009 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —28,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —22,044 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —23,576 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —24,258 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,398 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —28,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —22,044 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —23,576 | filing |
News
No headline names them, or the companies they trade most, lately.